Abstract
The prognosis for patients with malignant gliomas remains dismal and novel therapeutic agents are urgently needed. We investigated the potential role of aromatase (CYP19A1), an enzyme that catalyzes the conversion of androgens to estrogens in peripheral tissues, as a target for the treatment of CNS malignancies, as well as brain disposition and anti-tumor efficacy of letrozole, an aromatase inhibitor. Two recent discoveries from our lab have immediate clinical import. First, we analyzed the expression of aromatase in 67 human biopsy samples obtained from the University of Cincinnati Cancer Institute Tumor bank. De-identified frozen tissue samples (containing at least 50 % tumor cells, confirmed by HE i.p. injections) had long term suppression with overall survival exceeding 65 days and no signs of overt toxicity. In contrast, control untreated rats (N = 6, 2ml/kg vehicle i.p. injections) developed significant morbidity/mortality in 15-20 days. Overall, our studies strongly suggest that aromatase is a new “druggable target” for treatment of HGGs and that letrozole can potentially be readily used for this purpose.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call